Wall Street Zen Downgrades Ralliant (NYSE:RAL) to Hold

Ralliant (NYSE:RAL) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

A number of other brokerages have also commented on RAL. TD Cowen upped their price target on Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 20th. Zacks Research upgraded shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 30th. Morgan Stanley boosted their target price on shares of Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 23rd. BMO Capital Markets initiated coverage on shares of Ralliant in a research note on Monday, July 20th. They set a “market perform” rating and a $78.00 target price for the company. Finally, Evercore started coverage on shares of Ralliant in a report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Ralliant has a consensus rating of “Moderate Buy” and a consensus target price of $73.00.

Ralliant Price Performance

NYSE RAL opened at $69.55 on Friday. Ralliant has a twelve month low of $37.27 and a twelve month high of $75.41. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The stock has a market capitalization of $7.78 billion and a PE ratio of -6.36. The stock has a 50-day simple moving average of $66.43 and a 200 day simple moving average of $53.80.

Ralliant (NYSE:RAL) last announced its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.08. The firm had revenue of $534.60 million during the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The business’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Research analysts anticipate that Ralliant will post 2.64 EPS for the current year.

Hedge Funds Weigh In On Ralliant

A number of hedge funds have recently modified their holdings of RAL. Phocas Financial Corp. boosted its stake in shares of Ralliant by 81.2% in the 4th quarter. Phocas Financial Corp. now owns 157,116 shares of the company’s stock valued at $7,999,000 after purchasing an additional 70,403 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Ralliant by 6.9% in the 4th quarter. Teacher Retirement System of Texas now owns 570,878 shares of the company’s stock worth $29,063,000 after purchasing an additional 36,800 shares during the last quarter. Alpha Omega Wealth Management LLC increased its position in shares of Ralliant by 615.8% during the 4th quarter. Alpha Omega Wealth Management LLC now owns 40,291 shares of the company’s stock worth $2,051,000 after purchasing an additional 34,662 shares in the last quarter. Walleye Capital LLC bought a new position in Ralliant during the 1st quarter valued at about $4,525,000. Finally, Fifth Third Bancorp lifted its holdings in Ralliant by 3,988.0% during the 1st quarter. Fifth Third Bancorp now owns 32,132 shares of the company’s stock valued at $1,336,000 after purchasing an additional 31,346 shares during the last quarter.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.